Search filters
Filters
Clear All

Phase

  • 2
  • 17
  • 1
  • 3
  • 28
  • 51
  • 36
  • 2
  • 49

Found 51 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Genetic Testing in Young Adults With Cancer Study

Genetic Testing in Young Adults With Cancer Study (Gen-Y)

18-40 years
All genders
Interventional
The overarching goal of our research is to define an evidence-based, sustainable approach to identifying and managing genetic risk among young adults with cancer and their relatives. Conventional practice leaves referral and testing decisions to mostly non-expert clinicians implementing complex guidelines at the point of care, leading to substantial under-utilization. …
Check Eligibility

A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors (ATRN)

18 years and older
All genders
Phase 1
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
Learn More

UPCC 33922: An Open-Label Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

99 years and younger
All genders
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
Learn More

UPCC 04122 A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy in Participants With Selected Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 12922: An Early Phase Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Activity of PEEL-224 in Patients with Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints).
Learn More

UPCC 32922: A Phase 1 First-in-Human Study of IK-930 an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol, Section 1.1.3. (Study Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints) Please refer to Protocol, Section 3. (Objectives and Endpoints)
Learn More

UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Learn More

UPCC 06922: A First-in-Human Open-label Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints) Please refer to Section 3 of the full protocol (Objectives and Endpoints)
Learn More

UPCC 26921: A Phase 1a/1b Open-label Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints)
Learn More

UPCC 38922: A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors

99 years and younger
All genders
Phase 1
Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints) Please refer to Protocol D9350C00001, Section 3 (Objectives and Endpoints)
Learn More
1 - 10 of 51